Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 83.8% in December

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 352 shares, a decrease of 83.8% from the December 15th total of 2,177 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 32,280 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 32,280 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Bolt Biotherapeutics Stock Up 3.1%

BOLT opened at $5.99 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57. The company has a market cap of $11.50 million, a price-to-earnings ratio of -0.27 and a beta of 0.91. Bolt Biotherapeutics has a one year low of $4.41 and a one year high of $11.70. The business’s fifty day moving average is $5.24 and its two-hundred day moving average is $5.48.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($3.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.07) by $1.35. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $0.82 million. Analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

Several large investors have recently modified their holdings of the business. Squarepoint Ops LLC increased its stake in shares of Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares in the last quarter. Shay Capital LLC acquired a new stake in Bolt Biotherapeutics during the 3rd quarter valued at $85,000. Finally, Susquehanna International Group LLP acquired a new stake in Bolt Biotherapeutics during the 3rd quarter valued at $89,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on BOLT shares. Zacks Research downgraded Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. HC Wainwright set a $7.00 target price on shares of Bolt Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $34.00.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.